Rasagiline

證據等級: L5

預測適應症: 6 個

Rasagiline: Repurposing Assessment — Incomplete Evidence Pack

One-Sentence Summary

Rasagiline (DrugBank ID: DB01367) is a candidate flagged for drug repurposing analysis, however the current Evidence Pack contains no predicted new indications, no original indication data, and no mechanism of action information. With three blocking or high-severity data gaps unresolved, a substantive repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Not available in current Evidence Pack
Predicted New Indication	No TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction not yet available; no supporting studies
Germany Market Status	✗ Not marketed (0 authorisations)
Number of Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the Evidence Pack received, Rasagiline (DB01367) has no original indication recorded and no TxGNN-predicted repurposing target has been generated. Without a predicted indication, it is not possible to evaluate mechanistic plausibility, disease-pathway overlap, or translational rationale at this time.

The absence of predicted indications is most likely attributable to missing upstream inputs: the meta.inputs_received field records only "drugbank" as a completed data source, suggesting that the knowledge-graph embedding or TxGNN inference step has not yet been executed against a complete input set.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — predicted indications, original indication text, and mechanism of action are all absent, leaving no repurposing hypothesis to evaluate. No clinical trial or literature search can be meaningfully scoped without a target indication.

To proceed, the following is needed:

Resolve DG002 (High) — Mechanism of Action: Query DrugBank API for DB01367 to populate original_moa. This is required before mechanistic plausibility can be assessed.
Resolve DG001 (Blocking) — Package Insert Warnings/Contraindications: Download and parse the TFDA or BfArM package insert PDF to populate safety fields. This blocks the S1 safety screen.
Re-run TxGNN inference: The predicted_indications array is empty. Verify that the KG embedding, DL prediction, and disease-mapping pipeline steps (Phase 2 per project SOP) have been executed for DB01367. Re-trigger the pipeline with a complete input set.
Populate original_indications: Confirm the approved indication(s) from the DrugBank record or regulatory source and backfill the field so the report title and Quick Overview can be completed.
Re-generate this report once the above gaps are resolved and predicted_indications[0] is populated.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.